Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Selective reduction of alkenes, α,β-unsaturated carbonyl compounds, nitroarenes, nitroso compounds, N,N-hydrogenolysis of azo and hydrazo functions as well as simultaneous hydrodehalogenation and reduction of substituted aryl halides over PdMCM-41 catalyst under transfer hydrogen conditions2004 · 62 citations
2. 2A systematic review of geographical variation in access to chemotherapy2015 · 407 citations
3. 3Phase 2 study of <scp>MK</scp>‐2206, an allosteric inhibitor of <scp>AKT</scp>, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (<scp>S</scp>1005)2015 · 89 citations
4. 4Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design2005 · 658 citations
5. 5A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer2017 · 74 citations